Administrative Supplement: Cervical Cancer Recurrence and the Vaginal Microbiome

Administrative Supplement: Cervical Cancer Recurrence and the Vaginal Microbiome is sponsored by National Cancer Institute (NCI). This administrative supplement supports the evaluation of changes in the vaginal microbiome and HPV strains in association with cervical cancer recurrence in survivors who have completed radiation therapy.

Administrative Supplement: Cervical Cancer Recurrence and the Vaginal Microbiome Project Number 3P30CA138292-14S3 Former Number 5P30CA138292-13 Contact PI/Project Leader RAMALINGAM, SURESH S PROJECT SUMMARY/ABSTRACT Worldwide, cervical cancer (CxCa) is the 4th most common cancer in women.

In the US, up to 60% of CxCa survivors will have persistent Human Papillomavirus (HPV), the causative agent of CxCa, and 35% will develop recurrent CxCa within 2 years of treatment. Microbes could influence outcomes through a wide variety of mechanisms, and the vaginal microbiome (VM) has been linked with persistent HPV and other infections, but the exact processes are poorly understood.

Here we propose a secondary analysis to evaluate the changes over time of the VM and HPV strains in association with CxCa recurrence in CxCa survivors who have been followed up to 2 years after completing radiation therapy. Available stored samples collected from 80 participants will be used in this study: 40 postmenopausal CxCa patients who, and 40 healthy age- and race-matched controls.

Vaginal swabs for microbiome sequencing, and cervicovaginal swabs for HPV genotyping have been collected at baseline before the initiation of cancer therapy, and at 3, 6 and 12 months post radiation therapy. We will obtain vaginal microbiome data via 16S rRNA sequencing as well as shotgun metagenomics in order to characterize the vaginal microbial communities.

HPV typing of all available samples will be performed to identify the 51 most commonly encountered types. All subjects have been monitored for at least 2 years post-treatment, which is the mean time at which cervical cancer recurs. Association analysis will be performed to link the microbial community types with the HPV types and persistence, and cervical cancer recurrence.

Understanding the role that the VM plays in persistent HPV infection and cancer recurrence can guide future interventional strategies such as probiotics, in order to effectively sustain a healthy vaginal microbiome that can protect against persistent infections in cancer survivors.

Public Health Relevance Statement PROJECT NARRATIVE Worldwide cervical cancer (CxCa) is the 4th most common cancer in women, and in the US, up to 60% of CxCa survivors will have persistent Human Papillomavirus (HPV), the causative agent of CxCa, with 35% developing recurrent CxCa within 2 years of treatment.

The vaginal microbiome (VM) has been linked with persistent HPV and other infections, but the exact processes are poorly understood. We propose to evaluate the changes over time of the VM and HPV strains in association with CxCa recurrence in CxCa survivors that have been followed for 2 years after their radiation therapy.

Cancer Cervical Cancer Clinical Research Infectious Diseases Microbiome Radiation Oncology Sexually Transmitted Infections Women's Health 16S ribosomal RNA sequencing Accounting Administrative Supplement Aftercare Age Bacterial Vaginosis Cancer Patient Cancer Survivor Clinical Communities Data Diagnosis Disease Equilibrium Event Exhibits Future Genotype Human Papillomavirus Human papilloma virus infection Infection Intervention Lactobacillus Link Literature Malignant Neoplasms Malignant neoplasm of cervix uteri Metabolic Metagenomics Microbe Monitor Outcome Pain Participant Patients Pilot Projects Play Postmenopause Probiotics Process Publishing Race Radiation therapy Recurrence Recurrent Malignant Neoplasm Research Resistance Resolution Ribosomal RNA Risk Factors Role Sampling Sexual Dysfunction Sexually Transmitted Diseases Shotguns Structure Swab Symptoms Time Treatment-related toxicity Urinary tract infection Vagina Vaginal Human Papilloma Virus Viral Woman Work cancer initiation cancer recurrence cancer therapy cervicovaginal chemotherapy chronic infection cohort follow-up health disparity host microbiota metagenomic sequencing microbial microbial community microbiome microbiome sequencing prospective recurrent infection secondary analysis sociodemographics treatment comparison treatment response vaginal infection vaginal microbiome vaginal microbiota INTERNAL MEDICINE/MEDICINE [Cancer Centers Study Section (A)[NCI-A]](https://public.

csr. nih.

gov/StudySections/StandingStudySections) Administering Institutes or Centers National Cancer Institute Assistance Listing Number Project Funding Information for 2023 NIH Categorical SpendingClick here for more information on NIH Categorical Spending No Sub Projects information available for 3P30CA138292-14S3 Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding.

This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 3P30CA138292-14S3 No Patents information available for 3P30CA138292-14S3 The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 3P30CA138292-14S3 No Clinical Studies information available for 3P30CA138292-14S3 No news release information available for 3P30CA138292-14S3 No Historical information available for 3P30CA138292-14S3 No Similar Projects information available for 3P30CA138292-14S3 ## Select options for export: